nrneph.2012.213 pf2

Nov 20, 2014

10 likes | 215 Views

Figure 2 Activation of C3 convertase is involved in both complement-mediated and immune-complex-mediated MPGN. Bomback, A. S. & Appel, G. B. (2012) Pathogenesis of the C3 glomerulopathies and reclassification of MPGN Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.213.

Share Presentation

Embed Code

Link

mpgn
c3 glomerulopathies
complement mediated
c3 convertase
figure 2 activation
immune complex mediated mpgn

roanna-barnett

Download Presentation

nrneph.2012.213 pf2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Figure 2Activation of C3 convertase is involved in both complement-mediated and immune-complex-mediated MPGN Bomback, A. S. & Appel, G. B. (2012) Pathogenesis of the C3 glomerulopathies and reclassification of MPGN Nat. Rev. Nephrol.doi:10.1038/nrneph.2012.213

nrneph

Figure 2 Features of subclinical or indolent ABMR, which is typically diagnosed in protocol biopsies performed at 3 months or 1 year after transplantation in kidney transplant recipients who have preformed DSAs and are receiving potent immunosuppressive conditioning.

130 views • 1 slides

nrneph.2013.22-pt1

Table 1 Studies in rats showing the involvement of vasopressin and V2Rs in CKDs, albuminuria and hypertension. Bankir, L. et al. (2013) Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat. Rev. Nephrol. doi:10.1038/nrneph.2013.22.

152 views • 1 slides

nrneph.2014.91-pf3

Figure 3 TLRs, NLRs and the NLRP3 inflammasome drive host defence and tissue repair mechanisms by the clearance of pathogens and cell debris and by regulation of repair pathways. Leemans, J. C. et al. (2014) Pattern recognition receptors and the inflammasome in kidney disease

119 views • 1 slides

nrneph.2012.214-pf2

Figure 2 Recovery of renal function is better with a shorter interval between onset of aHUS and initiation of eculizumab. Zuber, J. et al. (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.214.

144 views • 1 slides

nrneph.2013.110-pf1

Figure 1 Mechanisms by which aldosterone and/or MR activation induce oxidative stress, inflammation, and fibrosis. Brown, N. J. (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis Nat. Rev. Nephrol. doi:10.1038/nrneph.2013.110.

145 views • 1 slides

nrneph.2012.196-pf3

Figure 3 Comparison of a mild case and severe case of STEC-HUS treated at the University Hospital in Hamburg–Eppendorf during the German outbreak in 2011. Trachtman, H. et al . (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS

142 views • 1 slides

nrneph.2009.67-pf1

Figure 1 Renal survival of patients in our study with pauci-immune crescentic glomerulonephritis with and without ANCAs. Permission obtained from the American Society of Nephrology  Chen, M. et al. Antineutrophil cytoplasmic autoantibody negative pauci-immune crescentic glomerulonephritis.

136 views • 1 slides

nrendo.2013.64-pf2

Figure 2 Schematic representation of potential depot-specific differences between subcutaneous and visceral adipose tissue in mice with normal GH signalling, low GH signalling (such as Ghr –/– mice) or increased GH signalling (such as GH transgenic mice).

136 views • 1 slides

ncpendmet0594-pf2

Figure 2 Examples of whole body scans and whole body radioiodine retention either after administration of rhTSH or after THW.

66 views • 1 slides

ncponc0059-pf2

Figure 2 MRI scan obtained 2 weeks after admission and 1 week after initiation of corticosteroid therapy. Plotkin, SR et al. (2005) Facial numbness in a man with inguinal and retroperitoneal masses . Nat Clin Pract Oncol 2 : 54 – 58 10.1038/ncponc0059.

181 views • 1 slides

ncpuro0184-pf2

Figure 2 Polysomnography (hypnogram) coupled with penile tumescence recordings demonstrate three episodes of rapid eye movement sleep-related erection with pain and awakening. Karsenty G et al . (2005) Sleep-related painful erections Nat Clin Pract Urol 2: 256 –260 doi:10.1038/ ncpuro0184.

181 views • 1 slides

ncpneuro0804-pf2

Figure 2 A brain biopsy specimen stained with hemotoxylin and eosin showed foci of microglia and lymphocytes involving the leptomeninges and neuropil. Valcour V et al . (2008) A case of enteroviral meningoencephalitis presenting as rapidly progressive dementia

118 views • 1 slides

ncpgasthep0871-pf2

Figure 2 Factors influencing differential diagnoses of drug-related hepatitis in individuals with elevated levels of aspartate aminotransferase, alanine aminotransferase,  -glutamyltransferase, alkaline phosphatase and bilirubin (both conjugated and unconjugated).

159 views • 1 slides

nrneph.2012.214-pt1

Table 1 Evidence supporting the role of complement dysregulation and the benefit of C5 blockade in aHUS and C3G. Zuber, J. et al. (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.214.

151 views • 1 slides

nrneph.2012.214-pt2

Table 2 Clinical and genetic characteristics of 24 off-trial patients treated with eculizumab for overt aHUS. Zuber, J. et al. (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.214.

130 views • 1 slides

ncponc0820-pf2

Figure 2 The proteins involved in the RB1 and p53 pathways with some interactions with the P13K/PKB pathway. Collins VP (2007) Mechanisms of Disease: genetic predictors of response to treatment in brain tumors Nat Clin Pract Oncol 4 : 362 –374 doi:10.1038/ncponc0820.

79 views • 1 slides

nrrheum.2013.197-pf2

Figure 2 Suggested algorithm for assessment, monitoring and management of patients with RA‑ILD on biologic therapy. Jani, M. et al. (2013) The safety of biologic therapies in RA‑associated interstitial lung disease Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2013.197.

145 views • 1 slides

nrm2104-pf2

Garneau et al. Nature Reviews Molecular Cell Biology 8 , 113 – 126 (February 2007) | doi:10.1038/nrm2104.

96 views • 1 slides

nrm1835 pf2

Thiery et al. Nature Reviews Molecular Cell Biology 7 , 131 – 142 (February 2006) | doi:10.1038/nrm1835.

109 views • 1 slides

nrgastro.2009.20 pf2

Figure 2 A CT scan of a patient with a massive pseudocyst of the pancreas that compressed not only the stomach but also the duodenum. O'Keefe SJD (2009) A guide to enteral access procedures and enteral nutrition Nat Rev Gastroenterol Hepatol doi:10.1038/nrgastro.2009.20.

123 views • 1 slides

nrneurol.2014.178 pf2

Figure 2 Spatial patterns of task-free networks commonly investigated in neurodegenerative disorders. Pievani, M. et al. (2014) Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy Nat. Rev. Neurol. doi:10.1038/nrneurol.2014.178.

143 views • 1 slides

nrendo.2013.246 pf2

Figure 2 Transversal CT image of a typical small-bowel neuroendocrine tumour mesenteric metastasis (arrow). van Essen, M. et al. (2013) Neuroendocrine tumours: the role of imaging for diagnosis and therapy Nat. Rev. Endocrinol. doi:10.1038/nrendo.2013.246.

132 views • 1 slides

More Related